Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma.
Twenty consecutive metastatic renal cell carcinoma patients were treated with a combination of recombinant alpha-2a interferon (18 X 10(6) U three times weekly) and vinblastine (0.1 mg/kg every 3 weeks). Two patients (10% response rate; 95% confidence limits 1.23-31.7%) achieved partial response and 11 (55%) stable disease. Toxicity was significant but always acceptable: most frequently, patients complained of fever and flu-like symptoms (18 of 19 patients), fatigue (18 of 19 patients), worsening in performance status (15 of 19 patients), and anorexia (15 of 19). The combination of recombinant alpha-2a interferon and vinblastine is active in renal cell carcinoma.
Sertoli
M R
MR
Department of Medical Oncology, National Institute for Cancer Research, Italy.
Brunetti
I
I
Ardizzoni
A
A
Falcone
A
A
Guarneri
D
D
Boccardo
F
F
Martorana
G
G
Curotto
A
A
Sicignano
A
A
Rosso
R
R
D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D014747:Vinblastine / Q000008:administration & dosage / Q000627:therapeutic use*
D011994:Recombinant Proteins; D014747:Vinblastine; D007371:Interferon-gamma